Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Income from Continuing Operations of 6800000.0 for Q1 2026, down 90.0% year-over-year from 68000000.0 in Q1 2025, and up 112.45% quarter-over-quarter from 54600000.0 in Q4 2025.
Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 6800000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 90.0% year-over-year to 6800000.0; the TTM figure through Mar 2026 stood at 8600000.0 (up 93.47% YoY), while the FY2025 annual figure was 52600000.0, up 127.6% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6800000.0, up from 54600000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 114800000.0 in Q3 2024, with the low at 283100000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 49500000.0 (2023), against an average of 65052941.18.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 4932.43% in 2023, then soared 655.56% in 2025.
- Emergent BioSolutions' Income from Continuing Operations stood at 67000000.0 in 2022, then rose by 26.12% to 49500000.0 in 2023, then soared by 36.77% to 31300000.0 in 2024, then slumped by 74.44% to 54600000.0 in 2025, then surged by 112.45% to 6800000.0 in 2026.
- Business Quant data shows EBS's Income from Continuing Operations at 6800000.0 in Q1 2026, 54600000.0 in Q4 2025, and 51200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -180.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -180.20 Mn |
| Mar 31, 2026 | 6.80 Mn |
| Dec 31, 2025 | -54.60 Mn |
| Sep 30, 2025 | 51.20 Mn |
| Jun 30, 2025 | -12.00 Mn |
| Mar 31, 2025 | 68.00 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | 114.80 Mn |
| Jun 30, 2024 | -283.10 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | -49.50 Mn |
| Sep 30, 2023 | -263.40 Mn |
| Jun 30, 2023 | -261.40 Mn |
| Mar 31, 2023 | -186.20 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -87.10 Mn |
| Jun 30, 2022 | -56.40 Mn |
| Mar 31, 2022 | -3.70 Mn |
| Dec 31, 2021 | 177.90 Mn |
| Sep 30, 2021 | -32.70 Mn |